Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512
United States
609 495 2200
https://palatin.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 34
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Carl Spana Ph.D. | Co-Founder, President, CEO & Director | 979k | N/A | 1962 |
Mr. Stephen T. Wills CPA, MST | CFO, COO, Executive VP, Treasurer & Secretary | 910.55k | N/A | 1957 |
Burns McClellan | Vice President of Investor Relations | N/A | N/A | N/A |
Mr. Stephen A. Slusher Esq. | Chief Legal Officer | N/A | N/A | N/A |
Dr. Michael B. Raizman M.D. | Chief Medical Officer | N/A | N/A | N/A |
Mr. James E. Hattersley | Senior Vice President of Business Development | N/A | N/A | 1960 |
Mr. John Dodd Ph.D. | Senior Vice President of Preclinical Development | N/A | N/A | N/A |
Mr. Robert Jordan | Senior Vice President of Program Operations | N/A | N/A | N/A |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Palatin Technologies, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.